mds

Ofirnoflast (HT-6184) Receives Orphan Drug Designation from U.S. FDA for Myelodysplastic Syndromes

LEHI, Utah, Oct. 23, 2025 /PRNewswire/ -- Halia Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering therapies that target the root causes…

2 weeks ago

Halia Therapeutics Completes Enrollment in Phase 2a Clinical Trial of HT-6184 for Myelodysplastic Syndrome (MDS)

LEHI, Utah, June 4, 2025 /PRNewswire/ -- Halia Therapeutics, a clinical-stage biopharmaceutical company pioneering therapies inspired by genetic resilience, today…

5 months ago

Sameer Kanodia, Managing Director and CEO, Lumina Datamatics, and Vice Chairman and CEO, TNQTech, honored with ‘India’s Top 50 CEOs, MDs, and Founders’ Recognition by the Great Manager Institute for 2025

MUMBAI, India, June 3, 2025 /PRNewswire/ -- Sameer Kanodia, Managing Director and CEO, Lumina Datamatics, and Vice Chairman and CEO,…

5 months ago